GTB-5550 treatment for people with advanced solid tumors.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This first-in-human Phase 1a/1b trial is testing GTB-5550, a tri-specific killer engager (TriKE) that links an anti-CD16 arm, wildtype IL-15, and an anti-B7-H3 arm to activate and expand NK cells against cancer. The study begins with a dose-escalation Phase 1a to identify a safe dose and then proceeds to Phase 1b expansion cohorts in selected tumor types including castration-resistant prostate, breast, pancreatic, non-small cell lung, head and neck, ovarian, and urothelial cancers. Eligible adults must have histologically or cytologically confirmed advanced/metastatic disease with measurable disease per RECIST 1.1 (except mCRPC limited to bone) and must meet specified prior-therapy and organ function criteria. Participants receive systemic GTB-5550 and are monitored for safety, tolerability, immune effects, and any signs of anti-tumor activity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Measurable disease per RECIST 1.1. (Exception: mCRPC limited to bone metastasis is exempt from this requirement).
* Age 18 years or older at the time of consent, ECOG Performance Status 0 to 2
* Acute effects of any prior therapy must have resolved to baseline or Grade ≤ 1 NCI CTCAE v5 except for AEs not constituting a safety risk in the opinion of the enrolling Investigator.
* Adequate organ function within 14 days (30 days for cardiac) of Cycle 1 Day 1 defined as:
* Hematologic: hemoglobin ≥ 9 g/dL (may be transfused not more than 2 units of pRBCs within 7 days prior to Cycle 1 Day 1 to meet this requirement); absolute neutrophil count (ANC) ≥ 1500/ul (granulocyte colonystimulating factor (s) is not allowed to achieve ANC threshold or within 7 days of Cycle 1 Day 1); platelets ≥ 100 x 10\^9/L (may be transfused not more than 2 units of platelets within 7 days prior to Cycle 1 Day 1 to meet this requirement); absolute lymphocyte count (ALC) ≥ 300/ul.
* Albumin ≥ 3.0 g/dL.
* Renal: a patient BSA corrected glomerular filtration rate ≥ 45 mL/min as calculated using the Modified Cockroft-Gault equation (Rostoker et al. 2007).
* Hepatic: AST and ALT ≤1.5 x upper limit of normal (ULN) and total bilirubin ≤1.5 x ULN.
* Cardiac: New York Heart Association (NYHA) Class I or II ; left ventricular ejection fraction (LVEF) ≥ 45% by echocardiogram, MUGA, or cardiac MRI.
* Adequate pulmonary function with PFTs \> 50% FEV1 if symptomatic or known impairment.
* Sexually active couples of childbearing-potential must agree to use effective contraception or abstinence during treatment and for at least 4 months after the final dose of GTB-5550.
* Agrees to stay within a 60-minute drive of the study center through the Cycle 1 Day 15 visit for the Phase 1a study only.
* Provides voluntary written consent prior to the performance of any research related activity

Exclusion Criteria:

* Anti-cancer treatment including surgery, radiotherapy, chemotherapy, other immunotherapy, or investigational therapy within 14 days prior to the 1st dose of GTB-5550. Radioligand therapy requires at least 1 cycle washout (6 weeks for Pluvicto, 4 weeks for Xofigo).
* Prior organ allograft or allogeneic transplantation. An exception is made for FA patients with prior history of allogeneic hematopoietic stem cell transplant off immune suppressive therapy for \> 1 year.
* Pregnant or breastfeeding or planning pregnancy within 4 months after the last dose of GTB-5550.
* The potential risk of QT/QTc prolongation is unknown in humans receiving GTB-5550; therefore, either of the following is an exclusion criteria: QTc interval \> 480 msec at screening and/or a family history of long QT syndrome.
* Prior malignancy other than the one under treatment except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer which is currently in complete remission, or any other cancer from which the patient has been disease-free for 1 year after surgical or other definitive treatment.
* Active autoimmune disease that has required systemic treatment (except replacement therapy) within the past 1 year or any other diseases requiring immunosuppressive therapy while on study. Inhaled or topical steroids, and adrenal replacement steroid doses ≤10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
* Active systemic infection requiring parenteral antibiotic therapy. Any prior systemic infections must have resolved to Grade 1 or lower following optimal therapy.
* Psychiatric illness/social situations that in the judgement of the enrolling investigator would limit compliance with study requirements.
* Other illness or a medical issue that, in the judgement of the enrolling Investigator, would exclude the patient's participation.

Where it's running

• Masonic Cancer Center at University of Minnesota
  Minneapolis, Minnesota, United States Recruiting

Study contacts

• Study coordinator: Nicholas Zorko, MD
• Email: zorko004@umn.edu
• Phone: 612-625-3051

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MSK-TCR5 in adults with advanced solid tumors that have KRAS/HRAS/NRAS G12D

  This study tests MSK-TCR5 to see if it is safe for adults with advanced solid tumors carrying a KRAS, HRAS, or NRAS G12D mutation.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07638371

• BSI-082 Alone or with Trastuzumab Deruxtecan in Advanced Solid Tumors

  This early-stage study tests BSI-082 by itself and then with Trastuzumab deruxtecan to see if higher doses are safe and tolerable in adults with advanced or metastatic solid tumors.

  Recruiting Phase 1 The University of Texas Health Science Center at San Antonio · San Antonio, Texas · NCT07086768

• Testing XB628 for advanced or metastatic solid tumors

  This study is testing a new treatment called XB628 to see if it can help people with advanced or metastatic solid tumors by finding the right dose that is safe and effective.

  Recruiting at 11 sites Phase 1 Exelixis · San Francisco, California and 10 other locations · NCT06952010

• Evaluating NKT3964 for Adults with Advanced Solid Tumors

  This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.

  Recruiting at 17 sites Phase 1 NiKang Therapeutics, Inc. · Little Rock, Arkansas and 20 other locations · NCT06586957

• Testing a new treatment for advanced solid tumors

  This study is testing a new treatment called tolododekin alfa for people with advanced solid tumors that haven't improved with standard therapies to see how safe it is and how well it works.

  Recruiting at 5 sites Phase 1 Ankyra Therapeutics, Inc · Bethesda, Maryland and 4 other locations · NCT06171750

• Evaluating mutations in solid tumors using liquid biopsy and genome sequencing

  This study is trying to see if a blood test can find important gene changes in patients with advanced solid tumors to help doctors choose the best treatments for them.

  Recruiting Centro di Riferimento Oncologico - Aviano · Aviano, Pordonone · NCT06028724

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.